首页> 外文期刊>BMC Microbiology >Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions
【24h】

Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions

机译:减数基因组学方法和宿主-病原体蛋白-蛋白相互作用的富集分析鉴定核梭状芽孢杆菌中的靶标

获取原文
           

摘要

Background Fusobacterium nucleatum , a well studied bacterium in periodontal diseases, appendicitis, gingivitis, osteomyelitis and pregnancy complications has recently gained attention due to its association with colorectal cancer (CRC) progression. Treatment with berberine was shown to reverse F. nucleatum -induced CRC progression in mice by balancing the growth of opportunistic pathogens in tumor microenvironment. Intestinal microbiota imbalance and the infections caused by F. nucleatum might be regulated by therapeutic intervention. Hence, we aimed to predict drug target proteins in F. nucleatum , through subtractive genomics approach and host-pathogen protein-protein interactions (HP-PPIs). We also carried out enrichment analysis of host interacting partners to hypothesize the possible mechanisms involved in CRC progression due to F. nucleatum . Results In subtractive genomics approach, the essential, virulence and resistance related proteins were retrieved from RefSeq proteome of F. nucleatum by searching against Database of Essential Genes (DEG), Virulence Factor Database (VFDB) and Antibiotic Resistance Gene-ANNOTation (ARG-ANNOT) tool respectively. A subsequent hierarchical screening to identify non-human homologous, metabolic pathway-independent/pathway-specific and druggable proteins resulted in eight pathway-independent and 27 pathway-specific druggable targets. Co-aggregation of F. nucleatum with host induces proinflammatory gene expression thereby potentiates tumorigenesis. Hence, proteins from IBDsite, a database for inflammatory bowel disease (IBD) research and those involved in colorectal adenocarcinoma as interpreted from The Cancer Genome Atlas (TCGA) were retrieved to predict drug targets based on HP-PPIs with F. nucleatum proteome. Prediction of HP-PPIs exhibited 186 interactions contributed by 103 host and 76 bacterial proteins. Bacterial interacting partners were accounted as putative targets. And enrichment analysis of host interacting partners showed statistically enriched terms that were in positive correlation with CRC, atherosclerosis, cardiovascular, osteoporosis, Alzheimer’s and other diseases. Conclusion Subtractive genomics analysis provided a set of target proteins suggested to be indispensable for survival and pathogenicity of F. nucleatum . These target proteins might be considered for designing potent inhibitors to abrogate F. nucleatum infections. From enrichment analysis, it was hypothesized that F. nucleatum infection might enhance CRC progression by simultaneously regulating multiple signaling cascades which could lead to up-regulation of proinflammatory responses, oncogenes, modulation of host immune defense mechanism and suppression of DNA repair system.
机译:背景技术核梭形杆菌是一种在牙周疾病,阑尾炎,齿龈炎,骨髓炎和妊娠并发症中经过广泛研究的细菌,由于其与结直肠癌(CRC)的进展有关,最近受到关注。小碱治疗通过平衡肿瘤微环境中机会性病原体的生长,逆转了小鼠核仁诱导的CRC进展。肠道菌群失衡和由核镰刀菌引起的感染可通过治疗干预来调节。因此,我们旨在通过扣除基因组学方法和宿主-病原体蛋白-蛋白相互作用(HP-PPI)预测核仁中的药物靶蛋白。我们还进行了宿主相互作用伙伴的富集分析,推测了由于核仁引起的CRC进展的可能机制。结果在消减基因组学方法中,通过搜索必需基因数据库(DEG),毒力因子数据库(VFDB)和抗生素抗性基因-ANNOTation(ARG-ANNOT),从核镰刀菌RefSeq蛋白质组中检索了必需,毒力和抗性相关蛋白。 )工具。随后的鉴定非人类同源,代谢途径独立/途径特异性和可药物化蛋白质的分级筛选产生了八个途径独立和​​27个途径特异性可药物化靶标。 F. nucleatum与宿主的共聚集诱导促炎基因表达,从而增强肿瘤发生。因此,从IBDsite,炎症性肠病(IBD)研究的数据库以及大肠腺癌中涉及的蛋白质(如The Cancer Genome Atlas(TCGA)所解释的)中的蛋白质被检索到,以基于带有F.nucleatum蛋白质组的HP-PPI预测药物靶标。对HP-PPI的预测显示出103种宿主蛋白​​和76种细菌蛋白所产生的186种相互作用。细菌相互作用的伙伴被认为是假定的目标。对宿主相互作用伙伴的富集分析显示,统计学上富集的术语与CRC,动脉粥样硬化,心血管,骨质疏松,阿尔茨海默氏病和其他疾病呈正相关。结论减法基因组学分析提供了一套靶标蛋白,对于核仁的存活和致病性而言是必不可少的。可以考虑使用这些靶蛋白来设计有效的抑制剂,以消除核镰刀菌感染。从富集分析中,假设核仁镰刀菌感染可能通过同时调节多个信号级联反应来增强CRC进展,这可能导致上调促炎反应,癌基因,调节宿主免疫防御机制和抑制DNA修复系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号